Core Viewpoint - AIM ImmunoTech Inc. announced a stock dividend of one share for every 1,000 shares of outstanding common stock and for every outstanding option or warrant that has a right to receive stock dividends, with the record date set for January 9, 2026, and distribution on January 13, 2026 [1]. Group 1: Stock Dividend Details - The stock dividend will be issued to stockholders and holders of Alternate Securities, with fractional shares rounded down and cash distributed for any remaining fractions based on a share price of $1.305, the average price on December 29, 2025 [2]. - Stockholders will not need to take any action to receive the stock dividend, as their accounts will be credited automatically, and brokers will receive the additional shares on behalf of stockholders [3]. Group 2: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being Ampligen (rintatolimod), a first-in-class investigational drug [4].

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Inovio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Dece ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth. ...

Key Points A Wells Fargo analyst cut his price target on Ultragenyx stock, though it still implies significant upside from yesterday's closing price. Ultragenyx reported yesterday that two Phase 3 studies failed to achieve primary endpoints for setrusumab. Despite the Wells Fargo analyst's positive outlook, Ultragenyx stock should only remain a consideration for those comfortable with more speculative investments. 10 stocks we like better than Ultragenyx Pharmaceutical › While Ultragenyx Pharmac ...

Group 1 - The article discusses the potential of Verastem, Inc. (VSTM) and highlights the RAMP-203 study as a significant opportunity for the company, particularly regarding the Avutometinib combination therapy [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis and a model portfolio of biotech stocks [2] - The Biotech Analysis Central service includes over 600 articles and aims to assist healthcare investors in making informed decisions [2] Group 2 - The article does not contain any specific financial data or performance metrics related to Verastem, Inc. or the biotech industry [1][3][4]

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Ultragenyx Pharmaceutical, Inc. for possible securities fraud following the failure of its clinical trials, which has led to a significant drop in the company's stock price [1][3]. Group 1: Company Performance - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies for setrusumab (UX143) did not meet their primary endpoint of reducing annualized clinical fracture rates compared to placebo and biophosphonates [3]. - Although the studies showed improvements in secondary endpoints related to bone material density, these did not correlate with a statistically significant reduction in fractures [3]. - Following the announcement, Ultragenyx's stock price fell by $14.87 (43.49%) to open at $19.32 per share, marking a new 52-week low, significantly below the previous low of $25.81 [3]. Group 2: Legal Actions - The Portnoy Law Firm is representing investors in pursuing claims related to corporate wrongdoing, and has a history of recovering over $5.5 billion for aggrieved investors [3]. - Investors are encouraged to contact the firm for a complimentary case evaluation and to discuss their legal rights regarding potential claims [2].

The cost of Wegovy is about to decrease significantly in a populous overseas market.Since pharmaceutical companies rely on the revenue generated from approved medicines, price cuts can put pressure on their fundamentals. That was the dynamic behind Novo Nordisk's (NVO 0.35%) fall on the stock market Monday; news that its Wegovy would cost less in a major market drove the company's shares down by nearly 2%. Chop, chopNovo Nordisk stated only that it was reducing the prices of its highly popular drug in China ...

Group 1: Johnson & Johnson - Johnson & Johnson has seen a significant price increase of 44% in 2025, with a price target bump to $217, approaching recent highs of around $215 [1][2] - The stock is currently trading below a key level of $207, which was previously an old high, indicating a potential resistance point [2][3] - Important moving averages are converging around $206-$207, suggesting this could be a pivotal point for future price movements [4] Group 2: SanDisk - SanDisk has demonstrated significant outperformance, rising from approximately $28 in April to over $284, although it has recently pulled back to around $245 [7][8] - The stock has established a trend line across its lows, indicating a strong upward trajectory despite recent fluctuations [9][10] - Notable resistance levels are identified at $240 and $283.10, with a potential breakout point above the downward sloping trend line [11][12] Group 3: Twilio - Twilio has received a price target increase from Citizens, raising it to $185 from $165, driven by optimism around AI integration in its business [16] - The stock has shown notable price activity, with key support levels around $140 and $130, while currently trading near $147 [21][23] - Technical indicators suggest that Twilio is in a bullish trend, with the RSI making new relative highs, indicating strength in the market [20][22]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Rezolute, Inc. and its officers or directors following disappointing clinical trial results that led to a significant drop in the company's stock price [1][3]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company on NASDAQ under the ticker RZLT [1]. - The company recently announced topline results from its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism [3]. Group 2: Clinical Trial Results - The Phase 3 study did not meet its primary endpoint, which was to assess the change in average weekly hypoglycemia events, showing only a 45% reduction in events at the highest dose of ersodetug (10 mg/kg), which was not statistically significant compared to a 40% improvement in the placebo group [3]. - The study also failed to meet its key secondary endpoint, with a 25% reduction in average daily percent time in hypoglycemia at the 10 mg/kg dose, again not statistically significant compared to a 5% increase in the placebo group [3]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial results, Rezolute's stock price fell by $9.44 per share, or 87.2%, closing at $1.77 per share on December 19, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving LENZ Therapeutics, Inc. following a significant drop in its stock price due to adverse event reports related to its product [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of LENZ Therapeutics, Inc. and is looking into whether the company and its officers or directors have engaged in fraudulent activities [1]. - The investigation was prompted by a report of a retinal tear associated with LENZ's VIZZ eye drop, which was recorded in the FDA's adverse event reporting systems [3]. Group 2: Stock Price Impact - Following the adverse event report on December 12, 2025, LENZ's stock price decreased by $6.36 per share, representing a decline of 25.96%, closing at $18.14 per share on that date [3]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].